Clovis Oncology Announces $170M Offering of Common Stock

Clovis Oncology

announced today that it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of $170 million. All shares of the common stock to be sold in the offering will be offered by Clovis Oncology. Clovis Oncology intends to use the net proceeds of the offering for general corporate purposes, including funding of its development programs, general and administrative expenses, acquisition or licensing of additional product candidates or businesses and working capital. J. P. Morgan Securities LLC and Credit Suisse Securities (USA) LLC are acting as joint book-running managers for the offering, and Leerink Swann LLC is acting as co-manager for the offering. In